Zomedica Corp

Insider buying surge at Zomedica Corp. shows director Johnny D. Powers adding 300,000 shares at $0.11, signaling confidence amid a small‑cap vet‑biopharma rebound.

Insider buying spurs optimism for Zomedica—CEO and execs are buying undervalued shares, hinting at a bullish future for this veterinary biopharma.

CEO Larry Heaton’s recent Zomedica share purchase signals confidence, with insider buying backing strong Q1 revenue growth and future product prospects.